The 33rd International Epilepsy Congress, taking place June 22-26, 2019 in Bangkok, Thailand, is a joint congress of the International League Against Epilepsy and the International Bureau for Epilepsy. The congress provides a forum for epilepsy specialists from around the world to come together, discuss the latest developments in basic and clinical epileptology, and network with fellow researchers, clinicians and other health care providers. The scientific program includes a wide range of main and parallel sessions, as well as teaching and video sessions.
The professor and chief of pediatric neurology at Le Bonheur Children’s Hospital and the University of Tennessee Health Science Center spoke about the concerns of uncontrolled epilepsy and how to determine if a patient requires more than one treatment for their epilepsy.
The pediatric neurologist and epilepsy specialist at Children’s Hospital Colorado discussed the popularity of cannabidiol from coverage in the media, and how she sees its use—and the understanding of it—evolving in the coming years.
The pediatric neurologist and epilepsy specialist at Children’s Hospital Colorado spoke about the need to continue to research therapies once they’re approved to better understand their use, and how cannabidiol falls into this category.
The director of the Jefferson Comprehensive Epilepsy Center spoke about the improvements that have come along with some of the surgical advancements in the treatment of epilepsy, specifically with laser interstitial thermal ablation.
The neurology resident at the University of California San Francisco discussed how new wearable technology and electronic diaries have helped improve the understanding of seizure rhythmicity, and ultimately, epilepsy care.
In order to improve patient care in epilepsy, physicians need a more consistent and cohesive method of recording patient seizure activity. As wearables get more sensitive and specific, using them in tandem with electronic seizure diaries may help address the challenge.
The neurology resident at the University of California San Francisco spoke about the role that seizure diaries can play in a patient’s peace of mind, as well as in the understanding of that patient’s response to a given treatment.
A trio of predictors may help inform which patients may be candidates for resective surgery, as well as improve the postsurgical consideration for re-operation on those who experience disabling seizure recurrence.
The professor of neurology at Cleveland Clinic’s epilepsy center discussed how algorithms can better influence the personalization of medicine, not just in the field of epilepsy, but in medicine as a whole.
Data suggest that rufinamide is capable of aiding in the control and reduction of seizures, as well as the possible achievement of seizure-freedom in pediatric patients with genetic/metabolic, hypoxic-ischemic, structural, and other intractable epilepsies.
The chief of neurology at Sree Chitra Tirunal Institute for Medical Sciences and Technology spoke about how to reassure patients with epilepsy who are planning for pregnancy and how to make treatment decisions with pregnant patients.
Several poster presentations at IEC 2019 suggest that the incidence of comorbid sleep disorders in people with epilepsy is higher than estimated and have a detrimental impact on quality of life and social adjustment.
The professor of epilepsy and medical education at St. George’s University Hospital London spoke about the number of challenges plaguing epileptologists when treating patients who present with possible status epilepticus in the hospital.
The professor of neurology at Cleveland Clinic’s epilepsy center spoke about the limitations of individual physicians in making clinical decisions, and how utilizing algorithm data can help improve epilepsy interventions.
Overall, myoclonic and absence seizures worsened in 1.2% and 15.9% more patients in the placebo group, respectively, than those given perampanel. The reductions in seizure frequency and the increases in seizure-free days were also greater with the noncompetitive AMPA receptor antagonist.
Preliminary results from the 4 mg maintenance period of the FREEDOM study, the first in which perampanel has been examined as monotherapy, were presented at the 2019 International Epilepsy Congress in Bangkok.